New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
Stocks in this Quantisnow insightHealth Care
Historical context for INDV
Across the 23 sessions after earlier INDV headlines, the stock closed higher 18 times and lower 5 times, with a median move of 1.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | INDV | SPY |
|---|---|---|---|
| May 14, 2026 | Indivior to Participate in Upcoming Investor Conferences | -1.4% | +0.8% |
| May 4, 2026 | Indivior Announces $175 Million Accelerated Share Repurchase | +3.5% | -0.4% |
| Apr 30, 2026 | Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance | +7.7% | +1.0% |
| Apr 24, 2026 | Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder | +0.2% | +0.8% |
| Apr 16, 2026 | Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse | -3.1% | +0.2% |
| Apr 9, 2026 | Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th | +1.2% | +0.6% |
Quantisnow market dataNASDAQ
INDV
Indivior Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for INDV
Full INDV profile on Quantisnow Follow INDV and get a push notification the moment its next story breaks.